FIELD: medicine.
SUBSTANCE: anti-aggregation preparation is introduced into platelet-rich plasma together with colloidal solution of glycosphingolipid (GSPL) liposomes, obtained by extraction of GSPL fraction from homogenate of pig brain. In process of preparation pretreatment colloidal solution of GSPL is mixed with solution of anti-aggregation preparation, after which obtained mixture is heated for 30 minutes at temperature 60°C.
EFFECT: increased efficiency of anti-aggregation preparation action and optimisation of anti-aggregation therapy of patients with cerebrovascular diseases.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PATIENT-SPECIFIC SELECTION OF ANTIPLATELET DRUGS FOR PATIENTS IN NEED THEREOF | 2012 |
|
RU2499261C1 |
| METHOD FOR STUDYING ANTI-AGGREGATION ACTION OF PREPARATIONS BY DETERMINING BLOOD PLATELET AGGREGATION IN VITRO | 2000 |
|
RU2188419C2 |
| 2-CYCLOALKYLAMINO-5-THIENYL-1,3,4-THIADIAZINES, HYDROBROMIDES, WITH ANTIAGGREGANT ACTIVITY | 2008 |
|
RU2379306C1 |
| ANTIPLATELET | 2023 |
|
RU2808529C1 |
| NITROESTER OF OXIDIZED STARCH SODIUM SALT SHOWING ANTIAGGREGANT ACTION | 1991 |
|
RU2074195C1 |
| METHOD OF DETERMINING ANTI-THROMBOTIC EFFECT OF ACETYLSALICYLIC ACID | 2007 |
|
RU2379684C2 |
| METHOD OF EVALUATING THE EFFECTIVENESS OF NON-AGGREGATE PREPARATIONS AFFECTING THE METABOLISM OF ARACHIDONIC ACID BY INHIBITION OF CYCLOOXYGENASE-1 BOTH INDIVIDUALLY AND JOINTLY WITH ADP P2Y RECEPTOR ANTAGONIST ON PLATELET MEMBRANES OF THE BLOOD TO THE PATIENT RECEIVING NON-AGGREGATE PREPARATIONS | 2010 |
|
RU2442167C1 |
| ANTIAGGREGATION AGENT | 1983 |
|
RU2045264C1 |
| METHOD FOR DETECTING ANTIPLATELET DRUG RESISTANCE IN PATIENTS WITH PROGRESSING CEREBRAL ATHEROSCLEROSIS | 2012 |
|
RU2478965C1 |
| METHOD OF INDIVIDUAL PROGNOSIS OF CLINICAL EFFECTIVENESS OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME | 2016 |
|
RU2639772C1 |
